IONQ Inc vs Nuwellis Inc — how do they compare? IONQ Inc trades at $39.4 (market cap $15.98B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: IONQ Inc is far larger — about 7263.6× Nuwellis Inc's market cap, and IONQ Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Nuwellis Inc for 26 Days on average.
| IONQ | NUWE | |
|---|---|---|
Market Cap | $15.98B | $2.20M |
Volume | 22,848,240 | 121,544 |
Sector | Technology | Health |
52-Week High | $82.09 | $146.65 |
52-Week Low | $26.59 | $0.68 |
Typical Hold Time | 33 Days | 26 Days |
Enterprise Value | $13.92B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.19, down 5.2% in the last session, with a bearish technical outlook despite recent positive analyst coverage. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a net income margin of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss following two consecutive beats. The stock remains 50% below analyst consensus price target of $62.75, indicating substantial upside potential if execution improves.
IONQ presents a high-risk, high-reward opportunity with Wall Street divided (50% buy, 50% hold). The bullish case hinges on quantum computing leadership and partnerships with major cloud providers, while risks include persistent losses, cash burn, and execution challenges in a nascent market. Current valuation metrics (P/S: 54.74) reflect growth expectations rather than current fundamentals.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →